Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$298.25 +0.5%	$282.12	$253.30 ▼ $346.85	$159.62B	0.49	2.84 million shs	1.52 million shs
BMY Bristol Myers Squibb	$47.02 -1.3%	$47.75	$39.35 ▼ $63.33	$96.93B	0.36	12.88 million shs	7.02 million shs
EXEL Exelixis	$45.91 +3.6%	$41.71	$21.86 ▼ $49.62	$12.08B	0.28	2.49 million shs	6.04 million shs
GILD Gilead Sciences	$111.28 -0.2%	$106.85	$66.01 ▼ $119.96	$138.71B	0.29	7.69 million shs	4.04 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.47%	+6.86%	+3.00%	+1.31%	-3.60%
BMY Bristol Myers Squibb	-1.31%	+0.71%	-2.25%	-15.01%	+17.36%
EXEL Exelixis	+3.63%	+6.54%	+7.59%	+32.80%	+109.06%
GILD Gilead Sciences	-0.21%	+3.40%	+1.78%	+3.75%	+67.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.2657 of 5 stars	2.2	2.0	3.3	3.9	3.4	2.5	0.6
BMY Bristol Myers Squibb	4.9028 of 5 stars	3.2	3.0	4.2	4.0	2.8	3.3	1.3
EXEL Exelixis	4.7468 of 5 stars	2.3	1.0	0.0	4.3	3.4	2.5	4.4
GILD Gilead Sciences	4.8426 of 5 stars	1.4	3.0	4.2	4.1	4.0	2.5	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.35	Hold	$307.82	3.21% Upside
BMY Bristol Myers Squibb	2.32	Hold	$58.00	23.36% Upside
EXEL Exelixis	2.52	Moderate Buy	$43.56	-5.13% Downside
GILD Gilead Sciences	2.78	Moderate Buy	$110.55	-0.66% Downside

Current Analyst Ratings Breakdown

Latest BMY, AMGN, EXEL, and GILD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	EXEL Exelixis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$47.00 ➝ $53.00
6/27/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$328.00
6/24/2025	EXEL Exelixis	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$50.00
6/24/2025	AMGN Amgen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/24/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00
6/24/2025	EXEL Exelixis	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$29.00 ➝ $60.00
6/23/2025	EXEL Exelixis	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/23/2025	EXEL Exelixis	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$43.00 ➝ $55.00
6/23/2025	EXEL Exelixis	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$47.00 ➝ $50.00
6/12/2025	EXEL Exelixis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $47.00
6/5/2025	EXEL Exelixis	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $46.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.80	$30.53 per share	9.77	$10.93 per share	27.29
BMY Bristol Myers Squibb	$48.30B	1.98	$5.81 per share	8.09	$8.08 per share	5.82
EXEL Exelixis	$2.17B	5.77	$2.00 per share	23.00	$7.86 per share	5.84
GILD Gilead Sciences	$28.75B	4.81	$6.86 per share	16.23	$15.44 per share	7.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	27.21	13.94	2.68	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.61	7.72	1.41	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
EXEL Exelixis	$521.27M	$2.20	20.87	18.00	0.89	27.99%	28.81%	21.94%	8/5/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	23.43	13.72	0.72	20.76%	51.93%	17.40%	8/6/2025 (Estimated)

Latest BMY, AMGN, EXEL, and GILD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.53	N/A	N/A	N/A	$11.32 billion	N/A
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.19%	N/A	86.86%	14 Years
BMY Bristol Myers Squibb	$2.48	5.27%	N/A	92.88%	17 Years
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.84%	N/A	66.53%	10 Years

Latest BMY, AMGN, EXEL, and GILD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	8.70	1.17	0.88
BMY Bristol Myers Squibb	2.65	1.28	1.17
EXEL Exelixis	N/A	3.50	3.44
GILD Gilead Sciences	1.16	1.37	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BMY Bristol Myers Squibb	76.41%
EXEL Exelixis	85.27%
GILD Gilead Sciences	83.67%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.76%
BMY Bristol Myers Squibb	0.09%
EXEL Exelixis	2.82%
GILD Gilead Sciences	0.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.71 million	533.62 million	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
EXEL Exelixis	1,147	272.71 million	265.02 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable

BMY, AMGN, EXEL, and GILD Headlines

Recent News About These Companies

Gilead Sciences Completes Long-Term Study on Filgotinib for Rheumatoid Arthritis

July 3 at 12:20 PM | tipranks.com

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Meritage Portfolio Management

July 3 at 8:07 AM | marketbeat.com

Teacher Retirement System of Texas Has $42.74 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

July 3 at 7:29 AM | marketbeat.com

First Horizon Advisors Inc. Sells 187,560 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

July 3 at 7:08 AM | marketbeat.com

DAVENPORT & Co LLC Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

July 3 at 5:18 AM | marketbeat.com

Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)

July 3 at 3:44 AM | msn.com

Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Rating of "Moderate Buy" from Analysts

July 3 at 2:13 AM | americanbankingnews.com

Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 3 at 2:11 AM | marketbeat.com

GILD - Gilead Sciences Inc Key Metrics - Morningstar

July 2 at 10:43 PM | morningstar.comM

Gilead Sciences’ Promising Phase II Study on Sacituzumab Govitecan for Solid Tumors

July 2 at 12:41 PM | tipranks.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

July 2 at 10:00 AM | prnewswire.com

Gilead Sciences, Inc. (NASDAQ:GILD) is Miller Howard Investments Inc. NY's 9th Largest Position

July 2 at 9:52 AM | marketbeat.com

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Moody Lynn & Lieberson LLC

July 2 at 8:51 AM | marketbeat.com

Vontobel Holding Ltd. Purchases 10,729 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

July 2 at 6:04 AM | marketbeat.com

Mather Group LLC. Acquires 6,731 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

July 2 at 6:02 AM | marketbeat.com

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Sells $1,104,500.00 in Stock

July 1 at 8:50 PM | marketbeat.com

Gilead Sciences: A Mixed Bag of Opportunities and Risks

July 1 at 8:23 PM | fool.com

Gilead Sciences CEO O'Day sells $1.1 million in stock

July 1 at 6:23 PM | investing.com

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Sumitomo Mitsui DS Asset Management Company Ltd

July 1 at 8:47 AM | marketbeat.com

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Rovin Capital UT ADV

July 1 at 7:44 AM | marketbeat.com

Alta Advisers Ltd Buys 2,400 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

July 1 at 7:06 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, AMGN, EXEL, and GILD Company Descriptions

Amgen NASDAQ:AMGN

$298.25 +1.40 (+0.47%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$298.25 0.00 (0.00%)

As of 07/3/2025 04:58 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Bristol Myers Squibb NYSE:BMY

$47.02 -0.62 (-1.29%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$47.02 0.00 (0.00%)

As of 07/3/2025 04:57 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Exelixis NASDAQ:EXEL

$45.91 +1.61 (+3.63%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$45.95 +0.04 (+0.09%)

As of 07/3/2025 04:41 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Gilead Sciences NASDAQ:GILD

$111.28 -0.24 (-0.21%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$111.28 0.00 (0.00%)

As of 07/3/2025 04:52 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time